View Older Stories View More Recent Stories
-
Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A PARDES BIOSCIENCES, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Tenaya Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CONCERT PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A SYNLOGIC, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A 5:01 Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Vera Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Orchestra BioMed Holding Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Magenta Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
-
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
-
Apogee Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer
-
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
-
Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria
-
Jnana Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
-
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
-
Form SC 13D/A Achilles Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Achilles Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Achilles Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Celcuity Closes $100 Million Private Placement
-
Form SC 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer
-
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
-
Vor Biopharma (VOR) Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
-
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
-
Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders
-
Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Solid Biosciences (SLDB) Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
-
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
-
Form SC 13G NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Research Alliance Corp. II Will Redeem Public Shares
-
Form SC 13D Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
Empatica receives new FDA clearance for its Health Monitoring Platform and announces Series B financing
-
Exo® CFO Lori Munoz Wins Stevie Award for Women in Business
-
Exo® CFO Lori Munoz Wins Stevie Award for Women in Business
-
Scribe Therapeutics to Participate in Four Upcoming Conferences
-
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
-
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
-
Adela's Co-Founder & Chief Scientific Officer to Deliver Plenary Session at American Association for Cancer Research (AACR) Special Conference on Precision Prevention, Early Detection, and Interce
-
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
